The Coach’s Team (TCT) offers the best in original, grassroots, conservative essays along with articles taken from various internet sites. The victory of Donald Trump has provided a God-sent opportunity to reverse the years of willful damage done our nation by Barack Hussein Obama, the most corrupt, treacherous and treasonous occupant of the White House in our near 240 existence. Coach's Team contributors pray Mr. Trump will indeed drain the swamp that is Washington DC.
Wednesday, May 17, 2017
Clinton Foundation distributed useless drugs to AIDS patients
The following article appeared on
World Net Daily (wnd.com) on April 25th of 2015. Lest we forget the unbounded
corruption of the Clinton family and its unalloyed dedication to amassing money.
Nice people, the Clintons.Ed
executive: 'It's just blacks dying'
As WND reported Wednesday, over the past six weeks, Charles Ortel shared with WND, prior to
publication, the results of his six-month, in-depth investigation into what he
characterizes as an elaborate scheme devised by the Clintons to enrich
themselves. WND reported Thursday the Clintons appear to have personally
profited from an airline-ticket levy program run by the U.N. group UNITAID that
used the Clintons’ international prestige to “leverage” manufacturers of
prescription quality drugs and health-care products and sell them to developing
countries at a discount price.
Ira Magaziner, the chief executive officer and vice
chairman of the Clinton Health Aids Initiative, known as CHAI, approached the
Indian company, Ranbaxy, in 2002 to negotiate a deal. It allowed CHAI to assume
a controlling position to administer the airline-ticket levy program through
UNITAID, a program of the U.N.’s World Health Organization in Geneva.
CHAI proposed to Ranbaxy that “they
could put the developing countries together to form a sort of ‘buying club’
that could “ramp up economies of scale and lower cost,” according to Professors
Ethan B. Kapstein of Arizona State University and Joshua W. Busby of the
University of Texas at Austin in their Cambridge University Press 2013 book “AIDS Drugs for All.”
A Kaiser Health News “Morning Briefing” dated Nov. 21, 2003, reported former President Bill Clinton “visited Indian generic drug
Ranbaxy Laboratories’ pharmaceutical plant in Gurgaon, India, to show support
for Indian companies that have agreed to manufacture low-cost generic
antiretroviral drugs for nationwide HIV/AIDS treatment plans in four African
and more than 12 Caribbean countries.”
hooks up with UNITAID and WHO
According to the UNITAID website, CHAI, established by
President Bill Clinton in 2002, approached UNITAID, created in 2006, “to reach
groups in developing countries that were neglected by HIV drug markets,”
resolving to combine forces in 2008.
The UNITAID-CHAI joint venture’s goal
was to combine UNITAID’s innovative financing that relied on levies charged on
airline tickets in participating countries with CHAI’s entrepreneurial approach
to getting international pharmaceutical companies to produce antiretroviral, or
ARV, drugs throughout the developed world at prices discounted because of the
massive scale of the market.
“The deal positioned the Clinton
Foundation to have access to hundreds of millions of dollars from what amounted
to a tax imposed on millions of average airline passengers,” explained Ortel.
“The Clinton Foundation financial reporting
strongly suggests the Clintons were able to skim off for their personal use
tens of millions of dollars from the funds WHO sent to CHAI from UNITAID
levies,” Ortel said.
“The scam was perfected,” he
concluded, “when a key player in developing the CHAI ‘discount generic drug’
strategy touted as revolutionary by Bill and Hillary Clinton, namely Ranbaxy in
India, achieved their ‘economy of scale’ by selling drugs the company knew were
so drastically substandard that the Ranbaxy ARV products had no chance of
curing any HIV/AIDS patients taking the drugs in the third world countries to
which the Clinton Foundation delivered them.
“It seems in hindsight a textbook case
of reckless and wanton neglect,” Ortel stressed.
The article captured the moral
bankruptcy of Ranbaxy through a conference call Dr. Kathy Spreen, Ranbaxy’s
executive director of clinical medicine, had with a dozen company executives in
which a participating Ranbaxy executives dismissed concern that the company was
producing defective drugs.
Ranbaxy executives plotted to blame
the problem on fraudulent tests run by one rogue contractor without disclosing
further problems that may have made it more difficult, if not impossible, to
re-establish WHO approval of Ranbaxy ARV drugs tested by labs other than Vimta.
The Fortune magazine exposé, however,
made clear Ranbaxy never stopped the subterfuge until forced to do so by the
Department of Justice settlement in 2013.
Fortune reported Ranbaxy “manipulated
almost every aspect of its manufacturing process to quickly produce
impressive-looking data,” including forging standard operating procedures to
hide from health inspectors the truth that Ranbaxy never stopped substituting
“cheaper, lower-quality ingredients in place of better ingredients, to
manipulate test parameters to accommodate higher impurities, and even to substitute
brand-name drugs in lieu of their own generics in bioequivalence tests to
produce better results.”
The Fortune article further exposed
“systematic fraud in Ranbaxy’s worldwide regulatory filings” designed to hide
that the majority of products filed in Brazil, Mexico, the Middle East, Russia,
Romania, Burma, Thailand, Vietnam, Malaysia and African nations “have data
submitted that did not exist or data from products and from other countries.”
Fortune noted Ranbaxy “not only
invented data but also fraudulently mixed and matched data, taking the best
results from manufacturing in one market and presenting it to regulators
elsewhere as data unique to drugs in their markets.”
For its HIV drugs, Fortune concluded
Ranbaxy “had used ingredients that failed purity tests and blended them with
good ingredients until the resulting mix met requirements,” such that “a
mélange cold degrade or become toxic far more quickly than drugs made from the
high-quality materials required.”
“The Ranbaxy tragedy,” Ortel pointed
out, “was that even after the Clintons had reason to suspect Ranbaxy was
producing defective ARV drugs for HIV/AIDS patients in Third World countries.
“Yet, CHAI continued to allow Ranbaxy
to sell Ranbaxy ARV drugs into the stream of pharmaceuticals that flowed to
desperately poor suffers, as if there were no problem.”
A UNITAID press release May 17, 2011, announced that since
2008, the CHAI partnership with UNITAID had “achieved price reductions that
will generate global savings of at least $600 million over the next three
years, making HIV treatment more widely available.”
“With more than nine million people
worldwide in need of HIV/AIDS treatment, we must see rapid action to increase
people’s access to treatment,” Clinton said in the UNITAID press release.
“Over 70 countries and 70% of the
HIV-infected population have access to the prices my Foundation negotiated; so
these new price reductions, which have been agreed to by a wide range of
suppliers, will provide millions of people with increased access to better,
cheaper and more convenient first and second-line drug regimens,” Clinton
continued. “We have helped almost four million people gain access to
life-saving medicine, and I’m proud that we can now reach millions more.”
What Clinton neglected to mention was
that since the formation of the CHAI partnership with UNITAID in 2008 through
the date of the 2011 press release, Ranbaxy ARV drugs were on the list of
CHAI-provided HIV/AIDS drugs available for distribution in Third World
Fortune made clear the Ranbaxy scam of
producing adulterated ARV drugs was known to Ranbaxy executives as early as
2004. It was made public in a U.S. Justice Department court filing in 2008 but
not stopped until January 2012, when the Justice Department placed Ranbaxy
under a sweeping consent degree the Justice Department described as “ground
breaking in its international reach.”
The UNITAID May 15, 2013, statement
mentioned in the last paragraph that Ranbaxy was among the CHAI/UNITAID “key
suppliers of ARVs.”
A CHAI-produced “Antiretroviral (ARV) Price List” dated May 2011 that includes Ranbaxy on the list of approved drugs boasted: “The
Clinton Health Access Initiative (CHAI) supports national governments to expand
high-quality care and treatment to people living with HIV/AIDS. CHAI offers
reduced prices for antiretrovirals (ARVs) to members of its Procurement
Yet, in a visit to Mumbai April 11,
2013, Bill Clinton praised Ranbaxy for its role in assisting his Clinton
Foundation in leading efforts to treat AIDS patients by agreeing 10 years
earlier to cut the price of its ARV drugs sold in developing nations.
“I told myself that never again will I
come to India without saying a thank you,” drawing applause from 600-plus
people who included “some of India Inc.’s leading CEOs, businessmen, and
strategists,” the Economic Times reported.
Despite Ranbaxy being in the process
of finalizing the $500 million settlement with the Department of Justice,
Clinton was as enthusiastic during his 2013 to India as he was 10 years
earlier, when on Nov. 21, 2003, he was there to announce the Ranbaxy deal.
In the speech, Clinton bragged the
Clinton Foundation in conjunction with Ranbaxy aimed to make low-cost ARV drugs
in the countries of South Africa, Rwanda, Mozambique, Tanzania, Haiti, the
Bahamas, the Dominican Republic and the Eastern Caribbean States with the goal
of making ARVs available to “some 2 million people around the world in the next
four to five years.”